<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093583</url>
  </required_header>
  <id_info>
    <org_study_id>FIBEA_04_EC_19_ALV</org_study_id>
    <secondary_id>2019-001167-75</secondary_id>
    <nct_id>NCT04093583</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial, Conventional Treatment-controlled, Studying the Efficacy of Plasma Rich in Growth Factor (PRGF®) in Alveolar Ridge Preservation After Simple Exodontia in the Anterior Region of Maxilla.</brief_title>
  <official_title>Randomized Clinical Trial, Conventional Treatment-controlled, Studying the Efficacy of Plasma Rich in Growth Factor (PRGF®) in Alveolar Ridge Preservation After Simple Exodontia in the Anterior Region of Maxilla.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Eduardo Anitua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Eduardo Anitua</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This RCT aims to study the efficacy and safety of PRGF-Endoret in alveolar ridge preservation
      in the aesthetic zone. The control group is the spontaneous healing occuring after the
      suturing of the alveolus. The primary endpoint is the bone regeneration measured in biopsies
      obtained from the regenerated alveolar bone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 7, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone regeneration</measure>
    <time_frame>12 months</time_frame>
    <description>Quantity of new bone measured in bone biopsies obtained after alveolar ridge preservation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Dental Implantation</condition>
  <arm_group>
    <arm_group_label>Simple suture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PRGF-Endoret</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exodontia</intervention_name>
    <description>Atraumatic exodontia followed by simple suture</description>
    <arm_group_label>PRGF-Endoret</arm_group_label>
    <arm_group_label>Simple suture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alveolar ridge preservation with a PRP (PRGF-Endoret)</intervention_name>
    <description>Filling of the alveolus with PRGF clot and fibrin plug.</description>
    <arm_group_label>PRGF-Endoret</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Preparation of PRGF using Endoret technology</intervention_name>
    <description>Preparation of PRGF using Endoret technology following manufacturer instructions</description>
    <arm_group_label>PRGF-Endoret</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Subjects of both sexes with an age greater than or equal to 18 years.

          -  Clinical indication for a simple exodontia in the aesthetic zone (from left 2nd
             premolar to the right 2nd premolar in the maxilla).

          -  Need of a dental implant placement in the extraction site.

          -  Availability to follow-up during the treatment period

          -  Subjects with non-active periodontal disease.

          -  Buccal dehiscence &lt; than 25% in the vestibular table

        Exclusion Criteria:

          -  - Presence of an active infection

          -  Loss of any plate of the socket

          -  Severe inflammation in the area of the exodontia previous to the intervention

          -  Have previous diagnosis of a coagulopathy.

          -  Have previous diagnosis of any autoinmune disease.

          -  Have received radiotherapy, chemotherapy or immunosuppressive treatments, systemic
             corticosteroids and/or anticoagulants the 30 days prior to inclusion

          -  Regular treatment with AINES or other antiinflammatory drugs

          -  Previous history of chronic hepatitis or heatic cirrhosis

          -  Positive markers for VHC, AgHBs, VIH I/II or Treponema pallidum

          -  Uncontrolled diabetes mellitus (Glycosylated hemoglobin higher than 9%)

          -  Subjects submitted to hemodyalisis

          -  Presence of malignant tumour, haemangiomas or angioma in the exodontia region.

          -  Previous history of ischemic cardiopathy in the last year.

          -  Pregnancy or womens in childbearing age who do not take contraception measures.

          -  Nursing womens

          -  Metabolic bone disease

          -  Ongoing treatment with biphosphonates both through oral or intravenous administration

          -  Smoking habits (&gt; 10 cigarrettes/day)

          -  In general, any disability to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sofía Fernandez de Retana, PhD, MBA</last_name>
    <phone>945 16 06 53</phone>
    <phone_ext>257</phone_ext>
    <email>sofia.fernandez@bti-implant.es</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exodontia</keyword>
  <keyword>PRGF</keyword>
  <keyword>alveolar ridge preservation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

